Recruitment of epitope-specific T cell clones with a low-avidity threshold supports efficacy against mutational escape upon re-infection.

Immunity

Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany; Partner site Munich, German Center for Infection Research (DZIF), Munich, Germany. Electronic address:

Published: June 2023

Repetitive pathogen exposure leads to the dominant outgrowth of T cell clones with high T cell receptor (TCR) affinity to the relevant pathogen-associated antigens. However, low-affinity clones are also known to expand and form immunological memory. While these low-affinity clones contribute less immunity to the original pathogen, their role in protection against pathogens harboring immune escape mutations remains unclear. Based on identification of the TCR repertoire and functionality landscape of naive epitope-specific CD8 T cells, we reconstructed defined repertoires that could be followed as polyclonal populations during immune responses in vivo. We found that selective clonal expansion is governed by clear TCR avidity thresholds. Simultaneously, initial recruitment of broad TCR repertoires provided a polyclonal niche from which flexible secondary responses to mutant epitopes could be recalled. Elucidating how T cell responses develop "from scratch" is informative for the development of enhanced immunotherapies and vaccines.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2023.04.010DOI Listing

Publication Analysis

Top Keywords

t cell clones
8
low-affinity clones
8
recruitment epitope-specific
4
t cell
4
epitope-specific t cell
4
clones
4
clones low-avidity
4
low-avidity threshold
4
threshold supports
4
supports efficacy
4

Similar Publications

An improved approach to generate IL-15/TGFβR2 iPSC-derived natural killer cells using TALEN.

Cell Rep Methods

September 2024

Cytovia Therapeutics, Inc., Natick, MA, USA. Electronic address:

We present a TALEN-based workflow to generate and maintain dual-edited (IL-15/TGFβR2) iPSCs that produce enhanced iPSC-derived natural killer (iNK) cells for cancer immunotherapy. It involves using a cell lineage promoter for knocking in (KI) gene(s) to minimize the potential effects of expression of any exogenous genes on iPSCs. As a proof-of-principle, we KI IL-15 under the endogenous B2M promoter and show that it results in high expression of the sIL-15 in iNK cells but minimal expression in iPSCs.

View Article and Find Full Text PDF
Article Synopsis
  • Natural killer (NK) cells are vital in the body's defense against cancer, and new antibody formats that enhance their activation are showing promise for immunotherapy, particularly through antibody-dependent cell-mediated cytotoxicity (ADCC).
  • Scientists have isolated two specific antibody clones, #1A2 and #2-2A2, that effectively target the CD16a receptor on NK cells without significantly affecting the related CD16b receptor on neutrophils, which may reduce unwanted side effects.
  • These antibodies can be combined with other tumor-associated antigens as bispecific antibodies, leading to effective NK cell activation and tumor cell destruction, offering potential for innovative cancer treatments that are less impacted by circulating human IgG.
View Article and Find Full Text PDF

Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization.

Front Immunol

July 2024

Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - "Fond G. Pascale", Naples, Italy.

Article Synopsis
  • The study explored the relationship between SARS-CoV-2 peptides and tumor-associated antigens (TAAs) to find if they could trigger similar immune responses.
  • Researchers identified that many SARS-CoV-2 proteins, particularly the Spike protein from the BNT162b2 vaccine, share significant amino acid sequences with TAAs linked to various cancers like breast and melanoma.
  • Findings suggest that prior infection or vaccination against COVID-19 could potentially offer immunity against certain cancers, opening avenues for developing new "multi-cancer" vaccines that exploit these viral similarities for therapeutic benefits.
View Article and Find Full Text PDF

Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.

Nat Commun

June 2023

Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland.

The success of cancer immunotherapy depends in part on the strength of antigen recognition by T cells. Here, we characterize the T cell receptor (TCR) functional (antigen sensitivity) and structural (monomeric pMHC-TCR off-rates) avidities of 371 CD8 T cell clones specific for neoantigens, tumor-associated antigens (TAAs) or viral antigens isolated from tumors or blood of patients and healthy donors. T cells from tumors exhibit stronger functional and structural avidity than their blood counterparts.

View Article and Find Full Text PDF

Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic 'cold' ovarian tumors. In order to treat a broader patient population, more TCRs targeting peptides derived from different TAAs binding in various HLA class I molecules are essential.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!